Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX · NASDAQ Global Market
-$0.02 today
Vol 0.10M · Avg 0.34M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PLYX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$6.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.10, tying the income statement back to per-share earnings.
Income Statement
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $888.0M | $1.0B | $809.6M |
| Cost of Revenue | $0 | $0 | $0 | -$1.7B | $344.8M | $725.6M |
| Gross Profit | $0 | $0 | $0 | $11.6B | $10.3B | $8.9B |
| Gross Margin | — | — | — | 26.4% | 45.5% | 9.8% |
| Research & Development | $6.3M +122.9% | $2.8M +1.4% | $2.8M | $1.2B | $378.4M | $983.2M |
| Selling, General & Admin | $1.6M +0.9% | $1.5M +52.6% | $1.0M | $811.0M | $1.4B | $620.6M |
| Operating Expenses | $7.8M +79.7% | $4.4M +15.1% | $3.8M | -$15.9B | $3.6B | $5.3B |
| Depreciation & Amortization | $0 | $0 | $0 | $419.0M | $1.2B | $374.2M |
| EBITDA | -$9.0M +70.4% | -$30.4M -703.3% | -$3.8M | $10.0B | $12.6B | -$15.2B |
| EBITDA Margin | — | — | — | 14.3% | 10.0% | 5.6% |
| Operating Income | -$7.8M -79.7% | -$4.4M -15.1% | -$3.8M | $9.0B | $10.6B | $12.3B |
| Operating Margin | — | — | — | 11.2% | 18.7% | 16.6% |
| Interest Income | $0 | $0 | $0 | $875.4M | $1.3B | -$1.5B |
| Interest Expense | $0 | $0 | $0 | $801.2M | $969.2M | $1.1B |
| Other Income / Expenses | -$1.2M +95.5% | -$26.0M -1300300.0% | $2.0K | $368.6M | -$1.6B | -$1.5B |
| Income Before Tax | -$9.0M +70.4% | -$30.4M -703.3% | -$3.8M | $13.9B | -$15.6B | $3.3B |
| Pre-Tax Margin | — | — | — | 15.4% | 13.3% | 20.8% |
| Income Tax Expense | $0 | $0 | $0 | $375.6M | $666.8M | $1.3B |
| Net Income | -$9.0M +70.4% | -$30.4M -703.3% | -$3.8M | $5.1B | $5.0B | $4.9B |
| Net Margin | — | — | — | 47.3% | 7.4% | 12.4% |
| EPS (Basic) | -$0 -18.8% | -$0 -700.0% | -$0 | $591.2M | $1.2B | $400.8M |
| EPS (Diluted) | -$0 -18.8% | -$0 -700.0% | -$0 | $777.4M | $620.6M | $766.2M |
| Weighted Avg Shares | $47.3M -75.0% | $189.4M +0.0% | $189.4M | $724.2M | $892.2M | $757.8M |
| Weighted Avg Shares (Diluted) | $47.3M -75.0% | $189.4M +0.0% | $189.4M | $566.0M | $319.6M | $1.2B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Jade Biosciences, Inc.
NASDAQ:JBIO
$551.66M
Crescent Biopharma, Inc.
NASDAQ:CBIO
$487.18M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$293.54M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$242.49M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$135.37M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$89.77M
Kezar Life Sciences, Inc.
KZR
$53.86M
Pelthos Therapeutics Inc.
PTHS
$17.96M
NextCure, Inc.
NXTC
$5.44M
HCW Biologics Inc.
HCWB
$2.22M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PLYX generate?
Polaryx Therapeutics, Inc. Common Stock (PLYX) reported $0.00 of revenue in fiscal 2025.
Is PLYX profitable?
Polaryx Therapeutics, Inc. Common Stock (PLYX) reported -$8,985,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.